• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·004720.KS
Share

PharmGen Science, Inc. Stocks

₩ 2770Last Updated 16.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

₩ 47.00M

₩ 2770
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PharmGen Science, Inc., originally founded in 1961 as Wooridul Pharmaceutical Limited, is a South Korean company primarily involved in the research, development, manufacturing, and distribution of pharmaceutical products. Based in Hwaseong, South Korea, the firm offers a diverse portfolio encompassing prescription medications, over-the-counter drugs, nutritional supplements, and cosmetic items. These are available in various forms, including tablets, hard capsules, granules, ointments, syrups, and suspensions.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is 'cheap' on EV/EBITDA, undervalued on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.10.2026 03:47

"It'll all blow over": Nvidia CEO Huang expressed confidence that the AI rally will continue

17.10.2026 03:37

"Musk Magic" Is Back: CFRA Analyst Raises Tesla's Price Target Due to the Flying Car

17.10.2026 03:20

Citi and BofA block AI agents from client accounts amid fears of deposit outflows

17.10.2026 02:40

Dollar posts worst week in over a month; euro snaps five-week losing streak

17.10.2026 01:32

The Nasdaq Composite IT sector index fell at its fastest pace in a week since June

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026